Skye BioscienceSKYE
SKYE
About: Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
Employees: 16
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
190% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 10
0% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]
0% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 13
1% less funds holding
Funds holding: 74 [Q3] → 73 (-1) [Q4]
1.72% less ownership
Funds ownership: 84.81% [Q3] → 83.09% (-1.72%) [Q4]
29% less capital invested
Capital invested by funds: $101M [Q3] → $71.3M (-$29.3M) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$14
567%
upside
Avg. target
$14.50
590%
upside
High target
$15
614%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Craig-Hallum Albert Lowe 29% 1-year accuracy 2 / 7 met price target | 567%upside $14 | Buy Maintained | 21 Mar 2025 |
Citizens Capital Markets Jonathan Wolleben 44% 1-year accuracy 30 / 68 met price target | 614%upside $15 | Market Outperform Reiterated | 21 Mar 2025 |
Financial journalist opinion
Based on 6 articles about SKYE published over the past 30 days
Neutral
GlobeNewsWire
4 hours ago
Skye Bioscience to Participate in May Investment and Medical Conferences
SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that it will participate in the following upcoming healthcare conferences: Investment Conferences Citizens Life Sciences Conference (New York)Presentation, Thursday, May 8, 11:00 am ET + 1x1 meetings Craig-Hallum Institutional Investor Conference (Minneapolis)1x1 meetings, Wednesday, May 28 Medical Conference European Congress on Obesity (Malaga, Spain)Poster presentation, May 13 Available webcasts will be accessible on Skye's website . About Skye Bioscience Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors.
Neutral
GlobeNewsWire
3 days ago
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, April 25, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that on April 23, 2025, the Board of Directors granted a non-qualified stock option award to purchase 19,000 shares of its common stock to one new non-executive employee under the Company's Amended and Restated 2024 Inducement Equity Incentive Plan (the “2024 Inducement Plan”). The stock options were granted as an inducement material to the employee entering into employment with Skye in accordance with Nasdaq Listing Rule 5635(c)(4).
Positive
Seeking Alpha
1 week ago
A Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash Value
Weight loss drug stocks like Novo Nordisk have dropped significantly lately. This presents potential value opportunities in a market projected to grow to $105 billion by 2035. Skye Bioscience's nimacimab, in Phase 2a trials, shows promise with significant weight loss results in mouse models, making it a speculative but potentially rewarding investment. 26-week results for the Phase 2a are expected in late Q3 or early Q4, so positive catalysts are on the horizon.
Positive
Benzinga
1 week ago
Skye Bioscience's Obesity Candidate Shows 30% Weight Loss When Combined With Eli Lilly's Blockbuster Drug In Animal Models
Skye Bioscience, Inc. SKYE stock is trading higher on Tuesday with a strong session volume of 18.49 million compared to the average volume of 196.131k, as per data from Benzinga Pro.
Neutral
GlobeNewsWire
2 weeks ago
Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model
Nimacimab shows comparable weight loss to monlunabant and tirzepatide alone, and an additive effect in combination with tirzepatide, in diet-induced obesity model New in vitro data demonstrates superior potency of nimacimab's differentiated and favorable mechanism of inhibition versus monlunabant Nimacimab Phase 2a CBeyond™ top-line randomized data expected late Q3/early Q4 2025 SAN DIEGO, April 15, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced new preclinical data for its novel CB1 antibody, nimacimab. In a murine diet-induced obesity (DIO) model, after 25 days of treatment, results demonstrated: Greater than 30% weight loss when nimacimab was combined with the dual GLP-1/GIP agonist, tirzepatide Nimacimab alone demonstrated 23.5% weight loss, comparable to monlunabant and tirzepatide alone.
Neutral
GlobeNewsWire
2 weeks ago
Skye Bioscience to Conduct Meetings at Piper Sandler Conference
SAN DIEGO, April 14, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that its executive team will be available for 1x1 meetings at the Piper Sandler Spring Biopharma Symposium on April 17th in Boston, MA. About Skye Bioscience Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors.
Neutral
Seeking Alpha
1 month ago
Skye Bioscience, Inc. (SKYE) Q4 2024 Earnings Call Transcript
Skye Bioscience, Inc. (NASDAQ:SKYE ) Q4 2024 Earnings Conference Call March 20, 2025 4:30 PM ET Company Participants Bernie Hertel - Head of Investor Relations Punit Dhillon - President and Chief Executive Officer Kaitlyn Arsenault - Chief Financial Officer Chris Twitty - Chief Scientific Officer Tu Diep - Chief Operating Officer Puneet Arora - Chief Medical Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald & Co. Edward Tenthoff - Piper Sandler & Co. Jay Olson - Oppenheimer & Co. Inc. Andy Hsieh - William Blair & Company George Farmer - Scotiabank Jonathan Wolleben - Citizens JMP Securities Albert Lowe - Craig-Hallum Capital Group Operator Ladies and gentlemen, thank you for standing by. My name is Jale, and I will be your conference operator today.
Neutral
GlobeNewsWire
1 month ago
Skye Bioscience to Announce 2024 Financial Results on March 20th, 2025
SAN DIEGO, March 14, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will host a conference call on Thursday, March 20th at 1:30 p.m. PT/4:30 p.m. ET to discuss its 2024 fourth quarter and full-year financial results. An earnings press release will be issued after the market closes on March 20th.
Neutral
GlobeNewsWire
1 month ago
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that on February 24, 2025, the Board of Directors granted a non-qualified stock option award to purchase 56,000 shares of its common stock to two new non-executive employee under the Company's Amended and Restated 2024 Inducement Equity Incentive Plan (the “2024 Inducement Plan”). The stock options were granted as an inducement material to the employee entering into employment with Skye in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
2 months ago
Skye Bioscience to Present at TD Cowen Health Care Conference
SAN DIEGO, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that Punit Dhillon, Chief Executive Officer, will present a corporate overview and be available for 1x1 meetings at the TD Cowen 45th Annual Health Care Conference.
Charts implemented using Lightweight Charts™